154
PolyActiva—a clinical-stage biopharmaceutical company whose technology enables precise drug delivery to the eye—may be headquartered in Melbourne, Australia, but three of its top leaders are based at the company’s Fort Worth office: CEO and Board Director Jerry St. Peter, CFO Wes Brazell, and Chief Scientific Officer, Michael Brubaker, PhD.
All three have previously worked together, but there’s another strategic reason for the North Texas leadership concentration: PolyActiva is focused on advancing its lead asset, a glaucoma treatment called PA5108, into Phase 2b clinical trials in the U.S.
Details in Dallas Innovates.
